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Objective: To evaluate the incidence and the clinical and echocardiographic features of infective
endocarditis (IE) caused by Staphylococcus lugdunensis and to identify the prognostic factors of surgery
and mortality in this disease.
Design: Prospective cohort study.
Setting: Study at two centres (a tertiary care centre and a community hospital).
Patients: 10 patients with IE caused by S lugdunensis in 912 consecutive patients with IE between 1990
and 2003.
Methods: Prospective study of consecutive patients carried out by the multidisciplinary team for diagnosis
and treatment of IE from the study institutions. English, French, and Spanish literature was searched by
computer under the terms ‘‘endocarditis’’ and ‘‘Staphylococcus lugdunensis’’ published between 1989
and December 2003.
Main outcome measures: Patient characteristics, echocardiographic findings, required surgery, and
prognostic factors of mortality in left sided cases of IE.
Results: 10 cases of IE caused by S lugdunensis were identified at our institutions, representing 0.8% (four
of 467), 1.5% (two of 135), and 7.8% (four of 51) of cases of native valve, prosthetic valve, and
pacemaker lead endocarditis in the non-drug misusers. Native valve IE was present in four patients (two
aortic, one mitral, and one pulmonary), prosthetic valve aortic IE in two patients, and pacemaker lead IE in
the other four patients. All patients with left sided IE had serious complications (heart failure, periannular
abscess formation, or shock) requiring surgery in 60% (three of five patients) of cases with an overall
mortality rate of 80% (four of five patients). All patients with pacemaker IE underwent combined medical
treatment and surgery, and mortality was 25% (one patient). In total 59 cases of IE caused by S
lugdunensis were identified in a review of the literature. The combined analysis of these 69 cases showed
that native valve IE (53 patients, 77%) is characterised by mitral valve involvement and frequent
complications such as heart failure, abscess formation, and embolism. Surgery was needed in 51% of
cases and mortality was 42%. Prosthetic valve endocarditis (nine of 60, 13%) predominated in the aortic
position and was associated with abscess formation, required surgery, and high mortality (78%).
Pacemaker lead IE (seven of 69, 10%) is associated with a better prognosis when antibiotic treatment is
combined with surgery.
Conclusions: S lugdunensis IE is an uncommon cause of IE, involving mainly native left sided valves, and it
is characterised by an aggressive clinical course. Mortality in left sided native valve IE is high but the
prognosis has improved in recent years. Surgery has improved survival in left sided IE and, therefore, early
surgery should always be considered. Prosthetic valve S lugdunensis IE carries an ominous prognosis.
S
taphylococci species constitute a very important group of
pathogens in infections of the cardiovascular system.
The pathogenic significance and aggressiveness of these
bacteria are well known.1 Staphylococcus lugdunensis was
initially described in 19882 as a separate species of coagulase
negative staphylococci. The pathogenic potential of this
microorganism has been clarified in a number of publications
describing predominantly infections of the skin and soft
tissues.3 In contrast to other staphylococcal endocarditis,
infective endocarditis (IE) caused by S lugdunensis has seldom
been reported in the past, and only case reports and brief case
series have been published.4–43 In this report we describe our
prospective experience with 10 new cases of IE caused by S
lugdunensis. In addition, we have extensively reviewed the
literature with the goal of providing more insight into the
incidence and the clinical and echocardiographic features of
IE caused by S lugdunensis, and the prognostic factors for
requiring surgery and mortality in this disease.
PATIENTS AND METHODS
Patient population
This prospective study of consecutive patients was carried out
by the multidisciplinary team for diagnosis and treatment of
IE from the Hospital Clinic of Barcelona and the Infectious
Diseases Unit from Mu´tua de Terrassa Hospital. The study
institutions are a tertiary referral centre for complicated
endocarditis and a community hospital, respectively, with a
catchment area of 1 050 000 inhabitants.
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We prospectively identified and followed up all patients
with IE admitted to both hospitals between 1990 and
December 2003. Data were collected prospectively with a
previously designed questionnaire that specified the clinical,
microbiological, echocardiographic, treatment, and evolutive
variables.44 Diagnosis of IE was established according to the
Duke criteria.45 Results of two dimensional transthoracic
echocardiography were routinely evaluated in all patients.
Transoesophageal echocardiography was performed for sus-
pected left sided endocarditis poorly defined by transthoracic
echocardiography and for suspected intracardiac complica-
tions (complicated IE) and in all cases of prosthetic valve
endocarditis.
Microbiology
All isolates of coagulase negative staphylococci are routinely
sent for speciation at our institutions. S lugdunensis has been
prospectively identified since 1996. All specimens of IE have
been prospectively collected since 1990 and coagulase
negative staphylococci were retrospectively investigated
to identify all isolates of S lugdunensis from the study
institutions.
S lugdunensis is a coagulase negative staphylococcus that
can be identified with considerable accuracy according to its
positive ornithine decarboxylase activity. All strains isolated
were identified as S lugdunensis on the basis of the following
phenotypic characteristics: coagulase negative, pyrrolidonyl
arylamidase positive, production of acetoine from glucose or
pyruvate, and production of acid from trehalose, mannose,
maltose, lactose, sucrose, and N-acetyl-glucosamide.46 A
commercial identification system (Api ID32 Staph,
bioMe´rieux, Marcy l’Etoile, France) was used. Susceptibility
to antimicrobial agents was determined by a disk diffusion
method and confirmed by a broth microdilution method. In
both cases, the recommendations stated in the National
Committee for Clinical Laboratory Standards were followed.47
Literature review
The English, French, and Spanish language literature from
1988 to December 2003 was searched by computer (Medline)
with the keywords ‘‘endocarditis’’ and ‘‘Staphylococcus lugdu-
nensis’’.
Statistical analysis
Data were processed with the BMDP (1990) statistical
package (BMDP Statistical Software, Inc, Los Angeles,
California, USA). Clinical and echocardiographic variables
for patients who required surgical treatment and for those
with adverse outcome were analysed with Student’s t test for
continuous variables and Fisher’s exact test for categorical
variables. The relation between covariates and requiring
surgery or mortality was assessed by univariate analysis.
Odds ratios (OR) were then determined with a logistic
regression model. The OR and 95% confidence intervals (CI)
were calculated by StataCorp 1999 (Stata Statistical Software,
release 6.0; Stata Corporation, College Station, Texas, USA).
An adjusted analysis was performed with models constructed
by multiple logistic regression analysis. Differences were
considered significant when two sided p was less than 0.05.
RESULTS
Patient characteristics
IE was diagnosed in 912 consecutive patients between 1990
and December 2003 in the study institutions; 259 cases of IE
were in injection drug users and 653 in the general
population. Ten cases of IE caused by S lugdunensis were
identified at the study institutions representing 1.1% of all
cases of IE, and 0.8%, 1.5%, and 7.8% of patients with native
valve, prosthetic valve, and pacemaker lead endocarditis,
respectively, in non-drug misusers (table 1). Table 2 sum-
marises clinical variables and outcome of patients from the
study institutions. Four patients had native valve IE (two
aortic, one mitral, and one pulmonary), two had prosthetic
valve aortic infection, and four had pacemaker lead endo-
carditis. All three patients with left sided native valve IE had
serious complications (heart failure, periannular abscess
formation, or shock) and two patients underwent surgery
but died. Endocarditis was diagnosed in the remaining
patient at necropsy. Prosthetic valve endocarditis was found
in two patients, both in the aortic position and both
complicated by periannular abscess formation; one patient
underwent surgery and one patient died. All four patients
with pacemaker lead endocarditis (three DDD and one VVI
pacemaker) underwent combined medical treatment and
surgery (complete removal of the pacing system) and
mortality in this subgroup was 25%.
Table 3 shows surgical rates and mortality according to the
staphylococcus species identified among all cases of staphy-
lococcal endocarditis diagnosed at the study institutions from
1990 to 2003. Rates of surgery for S lugdunensis IE were higher
than for IE caused by Staphylococcus aureus in the general
population (70% v 36.9%, OR 3.9, 95% CI 1.1 to 14.7) but not
higher than for Staphylococcus epidermidis IE (70% v 60%, OR
1.5, 95% CI 0.3 to 10.0). Mortality in S lugdunensis IE was
higher than in S aureus IE in the general population (50% v
14.5%, OR 5.9, 95% CI 1.6 to 21.2) and in S epidermidis IE (50%
v 20%, OR 4, 95% CI 1.1 to 14.9).
S lugdunensis IE was identified in 59 cases of IE from 40
articles in a comprehensive review of the literature from 1988
(initial description) up to December 2003.5–44 Table 4 shows
the combined analysis of the reported cases in the literature
and those from our institutions (69 cases). Native valve,
prosthetic valve, and pacemaker IE accounted for 77%, 13%,
and 10% of cases from the overall population. Native valve IE
(77% of cases) was characterised by mitral valve involvement
(55%), acute onset (54%), and frequent complications such
as heart failure (45%), periannular abscess formation (19%),
and peripheral embolism (30%). Surgery was performed in
51% of patients; mortality was 42% in the overall group and
29% in patients who underwent surgery. In native valve
disease, surgery was associated with improved survival (OR
3.2, 95% CI 1.1 to 8.9). Prosthetic valve endocarditis (13% of
cases) predominated in the aortic position (77%) and was
associated with extensive periannular tissue destruction
(abscess formation in 66% of cases). In this subgroup of
patients, surgery was performed in 55% and mortality was
78%. Pacemaker lead IE (10% of cases) was associated with a
benign prognosis. Antibiotic treatment combined with
surgery (extraction of all infected hardware) resulted in a
mortality of 14%.
Antibiotic treatment
Data on antibiotic susceptibility were obtained for 71% of
patients; 84% of strains were penicillin susceptible, 94% were
Table 1 Cases of infective endocarditis (IE) diagnosed
from 1990 to 2003 at both study institutions
Overall
Cases caused by
S lugdunensis
Injection drug users 259 0 (0%)
General population 653 10 (1.5%)
Native valve IE 467 4 (0.8%)
Prosthetic valve IE 135 2 (1.5%)
Pacemaker lead IE 51 4 (7.8%)
Total 912 10 (1.1%)
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methicillin susceptible, and all isolates were susceptible to
vancomycin, aminoglycosides, and rifampin. Data on anti-
biotic treatment were obtained for 81% of patients and for the
remaining patients antibiotic treatment was not specified.
b lactams alone (seven patients) or combined with other
antibiotics (aminoglycosides in 27, rifampin in one, or
cephalosporins in one) were administered to 36 patients.
Vancomycin alone (five patients) or combined with other
antibiotics (aminoglycosides in eight, rifampin in two,
cephalosporins in four, or imipenem in one) was adminis-
tered to 20 patients. Differences in mortality between the
antibiotic regimens were not significant (b lactams alone or
combined with other antibiotics versus vancomycin alone or
combined with other antibiotics, 52% v 35.5%, p = 0.35).
Required surgery in left sided endocarditis
Table 5 shows predictors of required surgery in left sided
endocarditis in the univariate analysis. Younger patients (age
, 50 years), absence of significant co-morbidity, aortic valve
involvement, and endocarditis complicated by formation of
periannular abscesses were significantly associated with
increased need for surgery. There was a trend towards
increased use of surgery in multivalvar IE and when the
clinical course was complicated with heart failure (table 5).
All the variables in the univariate analysis with p , 0.1 were
considered for multivariate analysis. Periannular abscess
formation (OR 5.4, 95% CI 1.2 to 23.4, p = 0.02) and
younger age (OR 4.9, 95% CI 1.3 to 18.9, p = 0.01) were
found to be independent prognostic factors for surgery.
Prognostic factors of mortality in left sided
endocarditis
Table 6 shows predictors of mortality in left sided endocardi-
tis in the univariate analysis. Age . 50 years, cases reported
before 1995, and absence of surgery were significantly
associated with increased mortality. Patients who did not
undergo surgery had a relative risk of mortality 2.9 times
(95% CI 1.0 to 8.7, p = 0.05) higher than those who were
operated on. All the variables in the univariate analysis with
p , 0.1 were considered for multivariate analysis. A diag-
nosis before 1995 (year of publication) (OR 3.3, 95% CI 1.1 to
11.4, p = 0.05) was the only independent prognostic factor
for mortality.
DISCUSSION
The various species of coagulase negative staphylococci
constitute the major component of the saprophyte flora in
humans. Although multiple species of coagulase negative
staphylococci have been described, only a minority infect
humans but they are the leading cause of prosthetic material
infection.1 In 1988, a new genomic species of coagulase
negative staphylococci was reported by Freney et al.2 This
species is readily differentiated from other coagulase negative
staphylococci by the production of ornithine decarboxylase
and pyrrolidonyl arylamidases. S lugdunensis can bind vitron-
ectin and fibrinogen to extracellular matrix proteins and may
be misidentified as S aureus because some isolates produce
clumping factor, resulting in positive slide coagulase or latex
agglutination tests. This may explain the disparity between
S lugdunensis isolates in coagulase negative staphylococci
Table 2 Clinical characteristics, management, and outcome of patients from the two institutions
Age
(years) Sex Co-morbidity
Valve involved, clinical
presentation Complications Surgery Outcome
77 F Liver cirrhosis, Le Veen shunt Native mitral, acute, no
echocardiography
Meningitis, CHF No Died in hospital
82 F Ischaemic heart disease Native atrial, acute, veg
12 mm
AMI, CHF, periannular
abscess
Yes Died in hospital
68* F DDD pacemaker 7 years, battery
replacement 1 year previously
Pacemaker lead veg
22 mm, early onset
None Yes Alive; relapse 1 year after initial
medical treatment: delayed
surgery (ET)
66 M DDD pacemaker 10 years previously Pacemaker lead veg
23 mm, late onset
Shock Yes (CPB) Died in hospital
78 M DDD pacemaker 5 years, battery
replacement 4 months previously,
chronic pocket infection
Pacemaker lead veg
10 mm, early onset
None Yes (ET) Alive
70 M Aortic valve surgery Aortic bioprosthesis,
acute, veg 8 mm
Periannular abscess,
shock
Yes Died in hospital
77 M Aortic valve surgery Aortic bioprosthesis,
chronic, no vegetation
Periannular abscess No Alive
43 F Congenital pulmonary stenosis Native pulmonary,
acute, no veg
None No Alive
37 M None Native aortic, acute,
veg, no veg
Peripheral embolism,
periannular abscess,
CHF, shock
Yes Died in hospital
63 M VVI pacemaker 15 years, battery
replacement 2 months previously,
chronic pocket infection
Pacemaker lead veg
8 mm, early onset
None Yes (ET) Alive
*Reported previously in reference 24.
Acute, duration of symptoms ,30 days; AMI, acute myocardial infarction; CHF, congestive heart failure; chronic, duration of symptoms .30 days; CPB,
cardiopulmonary bypass; early onset, symptoms ,12 months after surgical manipulation; ET, external traction; late onset, symptoms .12 months after surgical
manipulation; F, female; M, male; Veg, vegetation.
Table 3 Surgical rates and mortality according to the
staphylococcus species identified among all cases of
staphylococcal endocarditis diagnosed at the study
institutions (1990–2003)
Total Surgery Mortality
Staphylococcus aureus 310 63 (20.3%) 22 (7.1%)
Injected drug users 172 12 (7.0%) 2 (1.1%)
General population 138 51 (36.9%) 20 (14.5%)
Coagulase negative staphylococci 98 53 (54.0%) 23 (23.5%)
S epidermidis 75 45 (60.0%) 15 (20.0%)
S lugdunensis 10 7 (70.0%)* 5 (50.0%)
S hominis 6 1 (16.6%) 1 (16.6%)
Other species 7 2 (40.0%) 1 (14.2%)
*p,0.04 versus S aureus in the general population and not significant
versus S epidermidis; p,0.01 versus S aureus in the general population
and p,0.04 versus S epidermidis.
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endocarditis, which has been reported to be between 0%8
and 44%.32 It may also explain why endocarditis caused
by coagulase negative staphylococci is associated with a
subacute and indolent infection with few complications in
some reports48 and with an aggressive infection with valve
dysfunction, heart failure, and high mortality in others.49
Table 4 Overall clinical characteristics of 69 cases (10 from the two study institutions and
59 from the literature)
Clinical characteristics
Native valve
(n = 53)
Prosthetic valve
(n = 9)
Pacemaker lead*
(n = 7)
Mean age (years) 55 63 63
Age ,50 years 36% 11% 14%
Male sex 49% 33% 14%
Published before 1995 36% 77% 0%
Previous heart disease 38% 100% 100%
Co-morbidity` 30% 22% 14%
Known source of infection1 45% 33% 71%
Injection drug users 0% 0% 0%
Location
Mitral valve 55% 11% 0%
Aortic valve 28% 77% 0%
Tricuspid valve 0% 0% 0%
Pulmonary valve 4% 0% 0%
Pacemaker lead 0% 0% 100%
Multivalvar 13% 11% 0%
Acute onset (,30 days) 54% 11% 57%
Complications 60% 77% 14%
Heart failure 45% 22% 0%
Periannular abscess 19% 66% 0%
Embolisation 30% 11% 14%
Vegetation on echocardiogram 85% 22% 100%
Surgery 51% 55% 100%
Death 42% 78% 14%
Antibiotic + surgery 29% 80% 14%
Antibiotic alone (no surgery) 57% 75%** 0%
*Pacemaker (6), implantable cardioverter defibrillator (1); aortic (7) or mitral (1) prosthesis, rheumatic valve (6),
bicuspid aortic valve (3), mitral regurgitation (6), pacemaker (6), ischaemic heart disease (2), pulmonary stenosis
(1), implantable defibrillator (1); `AIDS (1), congestive heart failure (6), end stage renal disease (3), liver cirrhosis
(2), malignancy (2), rheumatoid arthritis (2), diabetes mellitus (1), lymphoma (1), renal transplant (1); 1cutaneous
infection (14), arteriovenous fistula or graft (5), vasectomy (4), arthritis (2), dental abscess (1), scrotal ulceration
(1), coronary angiography (1) or angioplasty (1), percutaneous valvoplasty (1), others (2); p,0.04 versus
antibiotic + surgery; **not significant versus antibiotic + surgery.
Table 5 Required surgery for left sided endocarditis caused by S lugdunensis (univariate
analysis of episodes reported between 1988 and 2003 plus cases from the study
institutions)
Variable n
Surgery
required OR (95% CI) p Value
Age .50 years 38 17 (45%) 1 0.01
,50 years 19 15 (79%) 4.6 (1.2 to 16.5)
Sex F 25 15 (60%) 1 0.6
M 32 17 (53%) 0.7 (0.2 to 2.2)
Previous heart disease* No 32 17 (53%) 1 0.6
Yes 25 15 (60%) 1.3 (0.4 to 3.8)
Co-morbidity* No 41 27 (66%) 1 0.02
Yes 16 5 (31%) 0.2 (0.07 to 0.8)
Source of infection* Unknown 33 19 (57%) 1 0.8
Known 24 13 (54%) 0.9 (0.3 to 2.5)
Endocarditic valve Prosthetic 8 5 (62%) 1 0.7
Native 49 27 (55%) 0.7 (0.1 to 3.4)
Valve involved Mitral 28 10 (36%) 1 0.003
Aortic 29 22 (76%) 5.6 (1.8 to 17.8)
Number of valves 1 49 26 (53%) 1 0.2
.1 8 6 (75%) 2.6 (0.5 to 14.4)
Acute onset (,30 days) No 10 6 (60%) 1 0.6
Yes 28 19 (68%) 1.4 (0.3 to 6.2)
Embolisation No 29 16 (55%) 1 0.3
Yes 17 12 (70%) 1.9 (0.5 to 6.9)
Diagnosis` ,1995 22 11 (50%) 1 0.5
.1995 35 21 (60%) 1.5 (0.5 to 4.4)
Periannular abscess No 41 19 (46%) 1 0.02
Yes 16 13 (81%) 5.0 (1.2 to 20.3)
Heart failure No 20 10 (50%) 1 0.2
Yes 26 18 (69%) 2.2 (0.7 to 7.5)
*Detailed in table 4; includes aortic valve involvement also in multivalvar infection; `year of publication.
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Characteristics of S lugdunensis endocarditis
S lugdunensis is a coagulase negative staphylococcus infect-
ing predominantly the skin and soft tissue and is only
occasionally responsible for IE.3 Owing to the prospective
design of this study, we calculated that S lugdunensis IE
accounted for only 1.1% of all cases of IE diagnosed at the
study institutions, and 0.8%, 1.5%, and 7.8% cases of native
valve, prosthetic valve, and pacemaker endocarditis, respec-
tively. The majority of patients acquired the infection in
the community and a site of entry was not identified for
some patients. Sources of infection have been reported to
be dental abscesses, cutaneous infection, infected vascular
accesses, infected pacemakers, vasectomies, and others
(table 4).
Some clinical determinants of S lugdunensis infection have
been reported previously and were confirmed in the present
investigation. In contrast to the indolent presentation
characteristic of native valve endocarditis caused by other
coagulase negative staphylococci, S lugdunensis causes valve
destruction and multiple complications similar to those in
endocarditis caused by S aureus. S lugdunensis IE is char-
acterised by a poor response to conventional antimicrobial
treatment, with important valvar destruction, myocardial
abscess formation, high peripheral embolic rate, and high
mortality, including cases referred for surgical treatment. The
majority of cases of IE caused by S lugdunensis involve native
valves (77%), whereas other coagulase negative staphylococci
(mainly S epidermidis) infect the prosthetic valve. Mitral and
aortic valve infection is often reported and in some cases
there is multivalvar endocarditis. Severe complications such
as heart failure and the need for valve replacement were
present in 45% and 51% of patients, respectively, compared
with 30–38% and 27–34% for other coagulase negative
staphylococci. In line with these data, surgical rates of S
lugdunensis IE from all cases of staphylococcal endocarditis
diagnosed at the study institutions were higher than surgical
rates for S aureus IE (table 3). Overall mortality is in the range
of 50%, which is considerably higher than the mortality
reported for other coagulase negative staphylococci (16%).1
As table 3 shows, we observed higher mortality for S
lugdunensis IE than for S aureus and S epidermidis IE. The
higher surgical rates and mortality of S lugdunensis IE are
probably due to the intrinsic virulence of this particular
organism. Endocarditis affected the prosthetic valve in only
13% of all cases but this type of infection is associated with
the highest complication rates and mortality. Surgery did not
reduce mortality in this subgroup of patients, probably
because of advanced periannular destruction and the low
number of patients.
Pacemaker lead endocarditis constitutes another subgroup
in S lugdunensis IE that has not been previously characterised.
Only seven cases have been reported, three from the
literature review22 26 and four from the present study.
Pacemaker lead endocarditis accounted for 7.8% of all cases
of IE from the study institutions, and when the entire pacing
system was extracted mortality was very low. Mortality from
electrode lead S lugdunensis IE is not different from mortality
caused by the general series of pacemaker lead endocarditis.50
Antibiotic susceptibil i ty and medical treatment
We observed no differences in terms of mortality between the
treatment options. Mortality rates did not differ between
treatment with b lactams alone or combined with other
antibiotics and treatment with vancomycin alone or in
combination, or between monotherapy and combined treat-
ment. There is no specific pattern of susceptibility to
antibiotics in endocarditis caused by S lugdunensis. This
makes the choice of antibiotics dependent on antibiotic
susceptibility tests. However, the majority of strains were
penicillin and methicillin susceptible. Despite the micro-
organism’s susceptibility in vitro, an antibiotic alone is
seldom successful and the majority of patients need surgery
during the active phase of the disease. S lugdunensis and S
aureus share similar morphology and both species produce
Table 6 Prognostic factors of mortality in left sided endocarditis caused by S lugdunensis
(univariate analysis of episodes reported between 1988 and 2003 plus cases from the
study institutions)
Variable n Mortality OR (95% CI) p Value
Age .50 years 39 24 (61%) 1 0.01
,50 years 19 5 (26%) 0.2 (0.06 to 0.7)
Sex F 26 12 (46%) 1 0.6
M 32 17 (53%) 1.3 (0.5 to 3.7)
Previous heart disease* No 33 16 (48%) 1 0.8
Yes 25 13 (52%) 1.1 (0.4 to 3.2)
Co-morbidity* No 42 20 (47%) 1 0.6
Yes 16 9 (56%) 1.4 (0.4 to 4.5)
Source of infection* Unknown 34 19 (56%) 1 0.3
Known 24 10 (42%) 0.5 (0.2 to 1.6)
Endocarditic valve Prosthetic 9 7 (77%) 1 0.08
Native 49 22 (45%) 0.2 (0.04 to 1.2)
Valve involved Mitral 28 14 (50%) 1 1.0
Aortic 30 15 (50%) 1.0 (0.3 to 2.8)
Number of valves 1 50 25 (50%) 1 1.0
.1 8 4 (50%) 1.0 (0.2 to 4.4)
Acute onset (,30 days) No 10 6 (60%) 1 0.2
Yes 28 11 (39%) 0.4 (0.1 to 1.9)
Embolisation No 30 13 (43%) 1 0.8
Yes 17 8 (47%) 1.2 (0.3 to 3.8)
Diagnosis` ,1995 23 16 (69%) 1 0.02
.1995 35 13 (37%) 0.2 (0.08 to 0.8)
Periannular abscess No 42 21 (50%) 1 1.0
Yes 16 8 (50%) 1.0 (0.3 to 3.1)
Heart failure No 20 8 (40%) 1 0.7
Yes 26 12 (46%) 1.3 (0.4 to 4.2)
Surgery Yes 32 12 (37%) 1 0.05
No 25 16 (64%) 2.9 (1.0 to 8.7)
*Detailed in table 4; includes aortic valve involvement also in multivalvar infection; `year of publication.
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clumping factor (bound coagulase) resulting in positive slide
coagulase and latex agglutination test. Negative tube
coagulase tests and positive pyrrolidonyl arylamidase,
ornithine decarboxylase, and mannitol fermentation tests
distinguish S lugdunensis from other clumping factor produ-
cing staphylococcus species. Prompt speciation can lead to
earlier recognition of S lugdunensis and earlier suspicion of IE
and, therefore, enables earlier medical treatment and surgery.
Surgery
The available clinical data suggest that S lugdunensis is an
aggressive pathogen. Frequent and severe in-hospital com-
plications and high mortality characterise S lugdunensis IE
even when surgery is performed early in the course of the
disease. Most patients had a short duration of symptoms,
usually for less than three weeks, and there was often gross
valvar destruction with abscess formation requiring valve
replacement (table 4). In our review, 51% of patients required
surgical intervention for native valve endocarditis, 55% for
prosthetic infection, and 100% for infected pacemakers. Some
subgroups of patients underwent surgery for left sided
endocarditis to reduce mortality; 57% of patients who did
not undergo surgery died compared with 29% of patients who
did have surgery (table 4). Deaths were common in the older
group, who were more likely treated conservatively. Absence
of significant co-morbidity, aortic valve involvement, and
endocarditis complicated by formation of periannular abscess
were significantly associated with increased use of surgery;
most deaths occurred in the earlier reports.
Prognosis
Mortality in IE caused by S lugdunensis is high, both for native
(42%) and prosthetic (78%) valves, although it has been
shown to have decreased in recent years (year of publication
after 1995). These figures are closer to those reported for IE
caused by other aggressive pathogens such as S aureus,51
group B streptococci,52 or pneumococci53 and are far from the
6% mortality in non-aggressive endocarditis caused by
viridans group streptococci.54 Cases reported before 1995
and older patients (age . 50 years) were significantly
associated with increased mortality. Patients with left sided
involvement who did not undergo an operation had a relative
risk of mortality 2.9 times higher than those operated on.
Although the proportion of patients referred for surgery for
left sided endocarditis did not differ substantially before and
after 1995 (50% v 60%, respectively), mortality decreased
from 69% to 37% during both time periods. Perhaps increased
recognition of this pathogen and its virulence has led to
earlier and more aggressive management including surgery.
Age and status of co-morbidities may have had an important
role in reducing mortality because younger patients without
significant co-morbidities had undergone more surgical
procedures with decreased mortality. Absolute numbers of
cases of prosthetic valve endocarditis caused by this organism
are very low, thus precluding analysis of factors influencing
mortality in prosthetic valve endocarditis. Surgical treatment
was not more often required for prosthetic valve endocarditis
than for native valves and surgery did not statistically reduce
mortality in prosthetic valve endocarditis. This is presumed to
be due to differences in baseline characteristics of patients,
differences in associated complications, the aggressive nature
of the infection, and the low number of patients.
Study limitations
This study has some limitations. There is a potentially
significant bias because, although the study was based on a
prospective analysis of cases at our institutions, the main
source of information was cases reported in the literature.
The severity of S lugdunensis endocarditis may appear higher
because cases with a complicated course and poor outcome
are more likely to be published. Subgroup analysis did not
show a reduction in mortality with the use of surgery in
certain subgroups of patients because of the retrospective
nature of the study, and there is a clear bias in selection of
the mode of treatment. A type II error due to the low number
of patients is probably the cause of this lack of benefit of
surgery in some subgroup of patients. However, this is the
largest analysis ever reported of IE caused by S lugdunensis.
Conclusion
S lugdunensis IE is an uncommon cause of IE involving mainly
native left sided valves. Despite the retrospective and non-
randomised nature of the study and the potential selection
bias, we conclude that S lugdunensis IE has an aggressive
course with high rates of severe in-hospital complications.
Therefore, all coagulase negative staphylococci should be
identified by species in all cases of complicated IE to allow
early identification of S lugdunensis. Mortality in left sided
native valve endocarditis is high but the prognosis has
improved in recent years. Surgery improved survival in left
sided IE and, therefore, early surgery should always be
considered. Prosthetic valve endocarditis due to S lugdunensis
carries an ominous prognosis.
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